233 related articles for article (PubMed ID: 25933719)
1. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
2. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
3. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
[TBL] [Abstract][Full Text] [Related]
4. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.
Glutig K; Bhargava R; Hahn G; Hirsch W; Kunze C; Mentzel HJ; Schaefer JF; Willinek W; Palkowitsch P;
Pediatr Radiol; 2016 Aug; 46(9):1317-23. PubMed ID: 27041276
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of gadoxetate disodium in elderly patients (≥65 years).
Endrikat J; Schwenke C; Vogtlaender K; Dohannish S; Breuer J
Acta Radiol; 2018 Jan; 59(1):81-88. PubMed ID: 28372493
[TBL] [Abstract][Full Text] [Related]
6. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
Endrikat J; Vogtlaender K; Dohanish S; Balzer T; Breuer J
Invest Radiol; 2016 Sep; 51(9):537-43. PubMed ID: 26964075
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.
Tsushima Y; Awai K; Shinoda G; Miyoshi H; Chosa M; Sunaya T; Endrikat J
Jpn J Radiol; 2018 Nov; 36(11):676-685. PubMed ID: 30232584
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
10. Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.
Prince MR; Lee HG; Lee CH; Youn SW; Lee IH; Yoon W; Yang B; Wang H; Wang J; Shih TT; Huang GS; Lirng JF; Palkowitsch P;
Eur Radiol; 2017 Jan; 27(1):286-295. PubMed ID: 26960538
[TBL] [Abstract][Full Text] [Related]
11. Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance.
Sessa M; Rossi C; Mascolo A; Grassi E; Fiorentino S; Scavone C; Reginelli A; Rotondo A; Sportiello L
Expert Opin Drug Saf; 2015; 14(9):1341-51. PubMed ID: 26156557
[TBL] [Abstract][Full Text] [Related]
12. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
13. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials.
Forsting M; Palkowitsch P
Eur J Radiol; 2010 Jun; 74(3):e186-92. PubMed ID: 19574008
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions to anthroposophic and homeopathic solutions for injection: a systematic evaluation of German pharmacovigilance databases.
Jong MC; Jong MU; Baars EW
Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1295-301. PubMed ID: 22692862
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
[TBL] [Abstract][Full Text] [Related]
17. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
19. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
[TBL] [Abstract][Full Text] [Related]
20. [Post-marketing safety profile of avocado-soybean unsaponifiables].
Olivier P; Montastruc JL;
Presse Med; 2010 Oct; 39(10):e211-6. PubMed ID: 20937576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]